Revisiting hypoxia therapies for tuberculosis

Revisiting hypoxia therapies for tuberculosis.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL:
Journal or Publication Title: Clinical Science
Volume: 133
Number: 12
Page Range: pp. 1271-1280
Date: 2019
Divisions: Immune-Vascular Interactions
Depositing User: General Admin
Identification Number: 10.1042/CS20190415
ISSN: 0143-5221
Date Deposited: 04 Jan 2021 23:45

The spectre of the coming post-antibiotic age demands novel therapies for infectious diseases. Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the single deadliest infection throughout human history. M. tuberculosis has acquired antibiotic resistance at an alarming rate with some strains reported as being totally drug resistant. Host-directed therapies (HDTs) attempt to overcome the evolution of antibiotic resistance by targeting relatively immutable host processes. Here, I hypothesise the induction of hypoxia via anti-angiogenic therapy will be an efficacious HDT against TB. I argue that anti-angiogenic therapy is a modernisation of industrial revolution era sanatoria treatment for TB, and present a view of the TB granuloma as a ‘bacterial tumour’ that can be treated with anti-angiogenic therapies to reduce bacterial burden and spare host immunopathology. I suggest two complementary modes of action, induction of bacterial dormancy and activation of host hypoxia-induced factor (HIF)-mediated immunity, and define the experimental tools necessary to test this hypothesis.

Oehlers, Stefan H.
Last Modified: 04 Jan 2021 23:45

Actions (login required)

View Item View Item